Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PHCC Priority Healthcare -- Ignore unavailable to you. Want to Upgrade?

To: afrayem onigwecher who wrote (102)	1/15/2002 2:27:05 PM
From: StockDung	Respond to of 103

Priority Healthcare Shares Fall After Analyst Downgrades Stock By Ambre Brown Morley Lake Mary, Florida, Jan. 15 (Bloomberg) -- Priority Healthcare Corp. fell as much as 16 percent after shares of the specialty pharmacy and drug distributor were downgraded by a Goldman, Sachs & Co. analyst. The shares fell $2.96, or 10 percent, to $26.66 in midmorning trading. Earlier, the shares touched $24.99. The shares have fallen 27 percent in the past 12 months. Priority Healthcare markets hepatitis C drug treatments for Schering-Plough Corp., which is requiring that patients register to receive its combination hepatitis C treatment Peg-Intron, or be place on a waiting list. Demand for Peg-Intron might exceed supplies of the drug as soon as next week, according to Schering- Plough. Priority Healthcare's shares were downgraded to ``market perform'' from ``market outperform'' by Goldman analyst Christopher McFadden, who called the company a ``victim of poor circumstance.'' McFadden hasn't returned a phone call seeking additional comment. In a separate report, Goldman, Sachs analyst James Kelly said that because overwhelming demand for Schering-Plough's treatment may outstrip supply, sales growth may be constricted. Shares of Schering-Plough fell 84 cents, or 2.4 percent, to $34.45. Last month, Schering-Plough said it couldn't guarantee Peg- Intron would be made available to patients who refused to participate in a registration system